Cargando…

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer

Colorectal cancer remains a major public health problem worldwide. Despite the introduction of antiangiogenic drugs for the treatment of metastatic disease, a large number of issues remains unresolved. In particular, studies on predictive biomarkers of response and pathways of resistance to these ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulivi, Paola, Marisi, Giorgia, Passardi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216829/ https://www.ncbi.nlm.nih.gov/pubmed/27081084 http://dx.doi.org/10.18632/oncotarget.8712

Ejemplares similares

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
por: Pirini, Francesca, et al.
Publicado: (2020)

Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
por: Molinari, Chiara, et al.
Publicado: (2018)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Molecular and Translational Research on Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2020)

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Ulivi, Paola, et al.
Publicado: (2021)

Special Issue on Basic and Translational Research in Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
por: Passardi, Alessandro, et al.
Publicado: (2021)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
por: Rodriguez-Pascual, Jesus, et al.
Publicado: (2017)

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2015)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer
por: Moisuc, Diana Cornelia, et al.
Publicado: (2022)

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors
por: Passardi, Alessandro, et al.
Publicado: (2023)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?
por: Cidon, E. Una, et al.
Publicado: (2016)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)

Antiangiogenic therapy for breast cancer
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2010)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
por: Hofheinz, R.-D., et al.
Publicado: (2016)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

Antiangiogenic Steroids in Human Cancer Therapy
por: Pietras, Richard J., et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_2maip0crjups8nnqdvn9m20vvl